Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
Source: View publication →
In patients with newly diagnosed advanced ovarian cancer who responded to first-line platinum-based chemotherapy plus bevacizumab, the addition of maintenance olaparib significantly improved overall survival specifically in those with homologous recombination deficiency (HRD)-positive tumors.
Key Findings
Study Design
Study Limitations
Clinical Significance
The PAOLA-1 trial establishes the combination of olaparib and bevacizumab as a standard-of-care maintenance regimen for patients with newly diagnosed, advanced HRD-positive ovarian cancer, demonstrating a long-term survival benefit that persists despite subsequent therapy.
Historical Context
The PAOLA-1 trial built upon the success of earlier studies (such as GOG 218 and ICON7) that established the role of bevacizumab in first-line maintenance, and the SOLO-1 trial, which demonstrated the efficacy of olaparib monotherapy in patients with BRCA-mutated ovarian cancer. It aimed to explore whether the addition of a PARP inhibitor could extend the benefit of anti-angiogenic therapy to a broader population, specifically those with HRD-positive status.
Guided Discussion
High-yield insights from every perspective
How does the concept of 'synthetic lethality' explain why olaparib is particularly effective in ovarian cancer patients with homologous recombination deficiency (HRD)?
Key Response
Synthetic lethality occurs when the simultaneous loss of two pathways leads to cell death, while the loss of either alone does not. Ovarian cancer cells with HRD (like BRCA mutations) have lost one double-strand break repair mechanism. PARP inhibitors (olaparib) block a different pathway (base excision repair for single-strand breaks). When single-strand breaks persist, they become double-strand breaks during replication; since the HRD cancer cell cannot repair these, it undergoes apoptosis, whereas normal cells with intact HRD pathways survive.
Based on the PAOLA-1 final OS data, which specific biomarker subgroup derives the greatest survival benefit from the addition of maintenance olaparib to bevacizumab, and how does this change your initial management plan for a newly diagnosed patient?
Key Response
The greatest OS benefit was seen in the HRD-positive subgroup (including both BRCA-mutated and BRCA wild-type HRD+ patients). In the HRD+ group, the 5-year OS rate was 65.5% with olaparib plus bevacizumab versus 48.4% with bevacizumab alone (HR 0.62). This mandates universal germline/somatic BRCA and HRD testing at diagnosis to identify patients who qualify for this specific combination maintenance therapy, as those who are HRD-negative (HRP) did not show a significant OS benefit from the addition of olaparib.
Compare the therapeutic implications of the PAOLA-1 final results with the SOLO-1 and PRIMA trials regarding the 'tail of the survival curve.' How should we interpret the lack of OS benefit in the HRD-negative (proficient) population in PAOLA-1 compared to the PFS benefits seen in other trials?
Key Response
While PAOLA-1 showed a massive OS benefit for HRD+ patients (confirming the curative potential seen in SOLO-1 for BRCAm), it showed no OS benefit in HRD-negative patients (HR 1.19). This contrasts with the PRIMA trial (niraparib), which showed a modest PFS benefit in the HRD-negative/HRP group. Fellows must recognize that statistically significant PFS gains do not always translate to OS, especially in HRD-proficient tumors where subsequent therapies and different tumor biology may dilute the effect of first-line PARP inhibition.
Given the 5-year OS data from PAOLA-1, how do you approach the 'financial toxicity' and cumulative side-effect profile of combination olaparib and bevacizumab versus olaparib monotherapy for a patient with a BRCA mutation?
Key Response
In BRCA-mutated patients, SOLO-1 established olaparib monotherapy as a standard, while PAOLA-1 showed a 5-year OS of 73.2% for the combination. However, there is no head-to-head trial comparing olaparib alone vs. olaparib + bevacizumab. An attending must weigh the added hypertension and proteinuria risks of bevacizumab against the potential incremental benefit, noting that for patients already receiving bevacizumab with chemotherapy, adding olaparib is the evidence-based path to maximizing OS in the HRD+ population.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The PAOLA-1 trial encountered significant 'crossover' or subsequent PARP inhibitor use in the control arm (bevacizumab only). Critically evaluate how this subsequent therapy impacts the interpretation of the Hazard Ratio for Overall Survival in the HRD-positive subgroup.
Key Response
In the HRD+ control group, approximately 50% of patients received a PARP inhibitor as a subsequent therapy. This usually leads to an underestimation of the true survival benefit of the experimental arm (dilution of effect). Despite this high crossover rate, the OS benefit remained statistically significant and clinically profound (HR 0.62), suggesting that early introduction of PARPi in the maintenance setting is superior to waiting for recurrence, even in HRD-sensitive tumors.
The PAOLA-1 study design lacked an 'olaparib monotherapy' arm. As an editor, how does this omission limit the ability to determine whether the survival benefit is synergistic or merely additive, and does this impact the trial's 'practice-changing' status?
Key Response
A three-arm trial (Bev, Olaparib, and Bev+Olaparib) would have been required to prove synergy. Without it, we cannot definitively say if bevacizumab adds value to olaparib in BRCAm patients. However, because the control arm reflected the then-standard of care (bevacizumab) and the HRD+ OS results were so robust, the study remains practice-changing. A reviewer would flag that we are essentially comparing a 'doublet' to a 'singlet' without knowing if the doublet is better than the alternative singlet (olaparib alone).
Current NCCN and ASCO guidelines prioritize HRD testing to determine maintenance strategies. How do the PAOLA-1 OS results specifically influence the level of evidence for recommending the combination of Olaparib and Bevacizumab in BRCA wild-type, HRD-positive patients compared to other PARP inhibitors?
Key Response
The PAOLA-1 OS data provides Level 1 evidence specifically for the olaparib+bevacizumab combination in the HRD-positive/BRCA wild-type subgroup, a group where OS benefit had been less certain. While guidelines like NCCN already included this (Category 1), the final OS data strengthens the recommendation from 'based on PFS' to 'confirmed by OS,' distinguishing it from niraparib (PRIMA) which has not yet demonstrated a significant OS advantage in the same first-line maintenance context.
Clinical Landscape
Noteworthy Related Trials
GOG-0218 Trial
Tested
Bevacizumab added to chemotherapy and continued as maintenance
Population
Newly diagnosed stage III or IV ovarian cancer
Comparator
Chemotherapy alone
Endpoint
Progression-free survival
SOLO-1 Trial
Tested
Olaparib maintenance
Population
Newly diagnosed advanced ovarian cancer with BRCA mutation
Comparator
Placebo
Endpoint
Progression-free survival
PRIMA Trial
Tested
Niraparib maintenance
Population
Newly diagnosed advanced ovarian cancer regardless of biomarker status
Comparator
Placebo
Endpoint
Progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis